The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Darren Sigal
Stock and Other Ownership Interests - Celularity; Cend Therapeutics; Karyopharm Therapeutics; Novartis
Honoraria - Ipsen
Consulting or Advisory Role - Celularity; Cend Therapeutics
Speakers' Bureau - Ipsen
Research Funding - Abivax; ARIAD/Incyte; OBI Pharma
Patents, Royalties, Other Intellectual Property - Patent on "a method for treating neuroendocrine tumors" using TRK inhibitors.
 
Kevin Berth
Employment - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
 
Adam Kuehn
Employment - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
Patents, Royalties, Other Intellectual Property - Celularity Inc
 
John Colerangle
Employment - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
 
Sharmila Koppisetti
Employment - Celularity Inc
Leadership - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
 
Shawn He
Employment - Celularity Inc
Leadership - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
Patents, Royalties, Other Intellectual Property - Celularity Inc.
 
William van der Touw
Employment - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
Patents, Royalties, Other Intellectual Property - Celularity, Inc. Patent applications in cell therapy resesearch and development
Travel, Accommodations, Expenses - Celularity Inc.
 
Robert Hariri
No Relationships to Disclose
 
Mark S. Awadalla
Employment - Celularity Inc
Stock and Other Ownership Interests - Celularity Inc
Patents, Royalties, Other Intellectual Property - Celularity Inc